Human Patents (Class 424/142.1)
  • Patent number: 11446377
    Abstract: Provided herein are methods of treating non-small cell lung cancers comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof and tremelimumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: September 20, 2022
    Assignee: MEDIMMUNE, LLC
    Inventors: Rajesh Narwal, Paul Robbins, Joyson Karakunnel, Mohammed Dar
  • Patent number: 11401336
    Abstract: Antibody species that bind B-Cell Maturation Antigen (BCMA) are provided as well as methods of depleting BCMA-expressing cells in a patient in need thereof, comprising administering a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof. Methods of treating B cell-related disorders associated with BCMA expression in a patient in need thereof are provided, comprising administering to the patient a therapeutically effective amount of the antibody species or an entity comprising a BCMA binding fragment thereof.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 2, 2022
    Assignee: CELGENE CORPORATION
    Inventors: Mahan Abbasian, Henry Chan, Kandasamy Hariharan, Jeonghoon Sun, Andrew Wurmser
  • Patent number: 11390679
    Abstract: Anti-LAG-3 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, an inflammatory disease, an autoimmune disease, type 1 diabetes, and/or infectious diseases.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: July 19, 2022
    Assignee: Phanes Therapeutics, Inc.
    Inventors: Minghan Wang, Hui Zou, Haiqun Jia
  • Patent number: 11371995
    Abstract: A method for selecting an individual to be a candidate for administration of an immune checkpoint inhibitor in treatment of a tumor, comprising: (1) a step of collecting a tumor tissue from the individual, (2) a step of determining the extent of B7-H3 expression in the tumor tissue collected in step (1), and (3) a step of selecting the individual as an individual to be a candidate for administration of the immune checkpoint inhibitor if the B7-H3 expression level is considered to be negative, is provided.
    Type: Grant
    Filed: December 25, 2017
    Date of Patent: June 28, 2022
    Assignees: Daiichi Sankyo Company, Limited, Kinki University
    Inventors: Kimio Yonesaka, Kazuhiko Nakagawa, Kenji Hirotani
  • Patent number: 11299543
    Abstract: This disclosure provides methods for treating a tumor in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD30 antibody. In some embodiments, the tumor is derived from a lymphoma (e.g., a Hodgkin lymphoma or a non-Hodgkin lymphoma). In certain embodiments, the anti-CD30 antibody is an antibody-drug conjugate, e.g., brentuximab vedotin.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 12, 2022
    Assignees: Bristol-Myers Squibb Company, Seattle Genetics. Tnc.
    Inventors: Benedetto Farsaci, Neil Josephson, Anthony Cao, Ryan Heiser
  • Patent number: 11292847
    Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: April 5, 2022
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Ashish Bansal
  • Patent number: 11292842
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 5, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Petra Rietschel, Israel Lowy
  • Patent number: 11278619
    Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 22, 2022
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David B. Weiner, Karuppiah Muthumani, Seleeke Flingai, Niranjan Sardesai
  • Patent number: 11267871
    Abstract: Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: March 8, 2022
    Assignee: Heiselberg ImmunoTherapeutics GmbH
    Inventors: Michaela Arndt, Jürgen Krauss, Dirk Jäger
  • Patent number: 11254752
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: February 22, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Alison Crawford
  • Patent number: 11242384
    Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 8, 2022
    Assignee: SANOFI
    Inventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
  • Patent number: 11220545
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Yanping Xiao
  • Patent number: 11213584
    Abstract: This invention relates methods of using a non-fucosylated anti-CD40 antibody for treatment of cancer and chronic infectious diseases.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: January 4, 2022
    Assignee: Seagen Inc.
    Inventors: Shyra Gardai, Che-Leung Law, Stanford Peng, Jing Yang, Haley Neff-LaFord
  • Patent number: 11167004
    Abstract: The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 receptor (IL-4R) inhibitor such as an anti-IL-4R antibody. In certain embodiments, the methods of the present invention are used to treat severe AD in a patient whose disease is not controlled with systemic therapy (e.g., cyclosporine A) or when such therapy is inadvisable.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: November 9, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Allen Radin, Neil Graham, Bolanle Akinlade, Gianluca Pirozzi, Xing Sun, Thomas Hultsch, Brad S. Shumel, Ashish Bansal
  • Patent number: 11136392
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: October 5, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu
  • Patent number: 11124569
    Abstract: The present invention relates to methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors, as well as diagnostic, prognostic, therapeutic methods and compositions related thereto.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: September 21, 2021
    Assignees: Dana-Farber Cancer Institute, Inc., President And Fellows Of Harvard College, Emory University
    Inventors: Gordon J. Freeman, Rafi Ahmed, Arlene H. Sharpe, Masao Hashimoto, Hyun T. Jin
  • Patent number: 11104733
    Abstract: The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: August 31, 2021
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Hollie Jaine Jackson, Cheng Liu
  • Patent number: 11053309
    Abstract: The present invention provides methods for treating, preventing or reducing the severity of active eosinophilic esophagitis. In certain embodiments, the present invention provides methods of increasing esophageal distensibility. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4/interleukin-13 (IL-4/IL-13) pathway inhibitor such as an anti-IL-4R antibody.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: July 6, 2021
    Assignees: Regeneron Pharmaceuticals, Inc., Sanofi Biotechnology
    Inventors: Allen Radin, Jennifer D. Hamilton, Leda Mannent
  • Patent number: 11041206
    Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: June 22, 2021
    Assignee: Cambridge Enterprise Limited
    Inventors: Paul A. Lyons, Kenneth G. C. Smith, Eoin F. McKinney, Daniele Biasci, James Lee
  • Patent number: 10982287
    Abstract: Recent large-scale analyses have demonstrated that the genomic landscape of human cancer is complex and variable among individuals of the same tumor type. Such underlying genetic differences may in part be responsible for the varying therapeutic responses observed in cancer patients. To examine the effect of somatic genetic changes in colorectal cancer on sensitivity to a common targeted therapy, we performed complete exome sequence and copy number analyses of 129 tumors that were KRAS wild-type and analyzed their response to anti-EGFR antibody blockade in patient-derived tumorgraft models. In addition to previously identified genes, we detected mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 as potential mechanisms of primary resistance to this therapy. Alterations in the ectodomain of EGFR were identified in patients with acquired resistance to EGFR blockade.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: April 20, 2021
    Assignees: The Johns Hopkins University, University of Torino
    Inventors: Victor Velculescu, Eniko Papp, Vilmos Adleff, Andrea Bertotti, Livio Trusolino
  • Patent number: 10941203
    Abstract: Provided is an isolated TrkB agonist antibody that binds to an epitope contained in one of the extracellular domains of TrkB and is capable of activating TrkB, wherein the extracellular domains comprises extracellular D1, D2, D3, D4, D5 domains and juxtamembrane domain of TrkB. Methods of using the TrkB agonist antibody in treating or reducing the risk of a TrkB associated conditions in a subject, wherein said condition is selected from cell differentiation, synaptic development, neural injury repairing and/or neurite branching.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 9, 2021
    Inventors: Bai Lu, Wei Guo, Hongyang Yao
  • Patent number: 10914747
    Abstract: The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: February 9, 2021
    Assignee: Dyax Corp.
    Inventors: Daniel J. Sexton, Ryan Faucette, Janja Cosic
  • Patent number: 10866241
    Abstract: The present invention relates to a method for the prognosis of bone metastasis in triple negative (including basal-like) breast cancer or, alternatively, ER+ breast cancer (including luminal A and B) which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF gene expression level, amplification or translocation. The invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The invention also relates to a c-MAF inhibitor as therapeutic agent for use in the treatment of triple negative (including basal-like) breast cancer metastasis or, alternatively, ER+ breast cancer (including luminal A and B) metastasis. The invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 15, 2020
    Assignees: INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS, FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)
    Inventors: Roger Gomis, Milica Pavlovic, Evarist Planet, Anna Arnal, Maria Tarragona
  • Patent number: 10857156
    Abstract: The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula I or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, wherein A, Q, n, m, R7, R8, V, X1, X2, X3, X4, X5, X6, and X7 are as defined herein, and at least one therapeutically active agents selected from immunotherapeutics, anticancer agents, and anti-angiogenics.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: December 8, 2020
    Assignee: SENHWA BIOSCIENCES, INC.
    Inventor: John Soong
  • Patent number: 10844118
    Abstract: The methods, compositions, and assays described herein are based, in part, on the discovery that CD1a mediates inflammation related to certain conditions such as urushiol exposure, psoriasis and other inflammatory skin diseases. One aspect provided herein relates to a method for treating or preventing an inflammatory skin disease, the method comprising: administering a therapeutically effective amount of an inhibitor of CD 1a to a subject having an inflammatory skin disease, thereby treating or preventing the inflammatory skin diseases.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: November 24, 2020
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Florian E. Winau, Ji Hyung Kim
  • Patent number: 10829551
    Abstract: The present invention relates to methods of modulating (e.g., reducing) the mannose content, particularly high-mannose content of recombinant glycoproteins.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 10, 2020
    Assignee: Amgen Inc.
    Inventors: Jian Wu, Nicole Sabo, Michael De La Cruz, Gregory Flynn
  • Patent number: 10736960
    Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: August 11, 2020
    Assignees: Omeros Corporation, University of Leicester
    Inventors: Nigel John Brunskill, Gregory A. Demopulos, Tom Dudler, Hans-Wilhelm Schwaeble
  • Patent number: 10722563
    Abstract: Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The recognition of HLA-A2 positive and PSGR expressing LNCaP cells was also tested. Three peptides, PSGR3, PSGR4 and PSGR14 frequently induced peptide-specific T cell responses in PBMCs from both healthy donors and prostate cancer patients, and are recognized by CD8+ T cells in an HLA-A2 dependent manner. These peptide-specific T cells recognize HLA-A2+ and PSGR+ tumor cells, and killed LNCaP prostate cancer cells in an HLA class I-restricted manner. These PSGR-derived peptides identified are useful as diagnostic markers as well as immune targets for anticancer vaccines.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: July 28, 2020
    Assignee: SHENZHEN INNOVATION IMMUNOTECHNOLOGY CO., LTD.
    Inventor: Rongfu Wang
  • Patent number: 10702473
    Abstract: A liposome formulation for delivery of Wnt signal pathway inhibitor is provided herein, which comprises lipid molecules and Wnt signal pathway inhibitor, wherein the liposome formulation is prepared through following steps: (1) providing an aqueous solution of the Wnt signal pathway inhibitor and providing an alcoholic solution of the lipid molecules, (2) mixing the aqueous solution of the Wnt signal pathway inhibitor and the alcoholic solution of the lipid molecules, (3) removing alcohol solvent to obtain the liposome formulation with Wnt signal pathway inhibitor encapsulated therein.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: July 7, 2020
    Assignee: Curegenix, Inc.
    Inventors: Yuhong Xu, Meiqing Tu, Xiaojing Chen
  • Patent number: 10688187
    Abstract: A liquid pharmaceutical composition having an anti-TNF? antibody, a buffer, a stabilizer, and a surfactant.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: June 23, 2020
    Assignee: INTAS PHARMACEUTICALS LTD.
    Inventors: Himanshu Gadgil, Chandresh Chhatbar, Vijaykant Pandey
  • Patent number: 10676520
    Abstract: Monoclonal antibodies and fragments thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: June 9, 2020
    Assignee: TRELLIS BIOSCIENCE, LLC
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista M. McCutcheon, Minha Park, Bo Chen, Ying-Ping Jiang
  • Patent number: 10590199
    Abstract: The present disclosure relates generally to antibodies and functional binding fragments thereof that bind to programmed death-ligand 1 (PD-L1). In particular, the disclosed antibodies and fragments bind to human PD-L1 and comprise novel complementary determining regions (CDRs) also disclosed herein. Finally, the present disclosure relates to administering the disclosed antibodies and fragments to subjects with cancer, thereby treating or slowing the progression or proliferation of the cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: March 17, 2020
    Assignee: CHECKPOINT THERAPEUTICS, INC.
    Inventors: Jonathan Belk, Nathan J. Sharkey, Leonid Gorelik
  • Patent number: 10550441
    Abstract: The invention provides a method for determining whether a human immunodeficiency virus is resistance to a viral entry inhibitor. The methods are particularly useful for determining resistance to inhibitors that act by a non-competitive mechanism. In certain aspects, the methods comprise determining whether an HIV population is resistant to an HIV entry inhibitor, comprising determining a log-sigmoid inhibition curve comprising data points for entry of the HIV population in the presence of varying concentrations of the HIV entry inhibitor, wherein if the entry of the HIV population cannot be completely inhibited by the HIV entry inhibitor, the HIV population is resistant to the HIV entry inhibitor.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: February 4, 2020
    Assignee: Monogram BioSciences, Inc.
    Inventor: Christos J. Petropoulos
  • Patent number: 10525035
    Abstract: Compositions and methods for the treatment of ocular diseases are disclosed.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 7, 2020
    Assignee: LANKENAU INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexander J. Muller, Arturo Bravo-Nuevo, Arpita Mondal, Courtney Smith, Hollie E. Flick
  • Patent number: 10513558
    Abstract: The invention relates generally to antibodies that specifically bind programmed cell death protein 1 (PD-1), activatable antibodies that specifically bind to PD-1 and methods of making and using these anti-PD-1 antibodies and anti-PD-1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: December 24, 2019
    Assignee: CytomX Therapeutics, Inc.
    Inventors: Kimberly Ann Tipton, James William West, Chanty Mariategue Chan
  • Patent number: 10508146
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: December 17, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Patent number: 10472623
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: November 12, 2019
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shinya Ishii, Atsuhiko Maeda, Takashi Nakai
  • Patent number: 10457725
    Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: October 29, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Matthew G. Fury, Israel Lowy
  • Patent number: 10428158
    Abstract: Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: October 1, 2019
    Assignee: Dyax Corp.
    Inventors: Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
  • Patent number: 10391100
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 27, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Mark Manfredi
  • Patent number: 10344088
    Abstract: This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 9, 2019
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Paul Andrew Hamblin, Alan Peter Lewis, Thomas Matthew Webb
  • Patent number: 10323083
    Abstract: Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 18, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Baron, Crystal Sao Fong Cheung, Julian Chun Kin Lui, Dimiter Dimitrov, Zhongyu Zhu
  • Patent number: 10307472
    Abstract: The present invention relates to a vaccine/agonist combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one OX40 agonist. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/agonist combination. Additionally the present invention relates to medical use of such a vaccine/agonist combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/agonist combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with an OX40 agonist.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 4, 2019
    Assignee: CureVac AG
    Inventors: Mariola Fotin-Mleczek, Karl-Josef Kallen, Jan C. Schmollinger
  • Patent number: 10288616
    Abstract: Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: May 14, 2019
    Assignees: Expression Pathology, Inc., The University Of Chicago
    Inventors: Daniel Catenacci, Todd Hembrough, Fabiola Cecchi, Wei-Li Liao
  • Patent number: 10253097
    Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: April 9, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Larry R. Pease, Virginia Van Keulen, Bogolub Ciric
  • Patent number: 10238698
    Abstract: The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: March 26, 2019
    Assignees: DNATRIX, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Frank Tufaro, Charles Conrad, Juan Fueyo-Margareto, Frederick Lang, Jr., Candelaria Gomez-Manzano, W. K. Alfred Yung, Amy Heimberger
  • Patent number: 10195273
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: February 5, 2019
    Assignee: SNIPR TECHNOLOGIES LIMITED
    Inventor: Jasper Clube
  • Patent number: 10166303
    Abstract: The present invention is directed to compositions and method for providing radio-imaging and radiotherapy for cancer. In particular, methods for making and using radio-labeled anti-HAAH antibodies for tumor imaging and immunotherapy are provided.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 1, 2019
    Assignee: Panacea Pharmaceutical Inc.
    Inventors: Hossein A. Ghanbari, Steven Andrew Fuller
  • Patent number: 10094835
    Abstract: This document provides methods and materials for treating patients following an assessment of immune subtypes such as an assessment of peripheral blood phenotypes. For example, methods and materials for treating a mammal having a medical condition after assessing a mammal's level of CD14+/DR? cells (e.g., CD14+/DR? monocytes) and level of CD4+ cells (e.g., CD4+ T cells) and classifying the mammal has being likely to experience a favorable or unfavorable medical outcome based at least in part on the mammal's level of CD14+/DR? cells and level of CD4+ cells are provided.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: October 9, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Allan B. Dietz, Michael P. Gustafson, Yi Lin
  • Patent number: 10066004
    Abstract: Inhibitor peptides for combinatorial inactivation of ErbB1, ErbB2, and ErbB3 featuring an EGFR-based peptide and a cell penetrating component such as a protein transduction domain (e.g., PTD4) for enhancing penetration of the EGFR-based peptide into a cell. The EGFR peptide may be from 8 to 30 amino acids in length. The inhibitor peptides can inhibit tumor growth, reduce metastasis, activate apoptosis, activate necrosis, disrupt calcium signaling, and/or increase ROS. In some embodiments, the EGFR-based peptide is at least 50% identical to at least 8 consecutive residues of SEQ ID NO: 1.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: September 4, 2018
    Assignee: ARIZONA CANCER THERAPEUTICS, LLC
    Inventor: Joyce A. Schroeder